Laboratory

Europe Laboratory Information Management System (LIMS) Market Insights Report 2023-2028: Rise in Remote Access Needs Boosts Cloud-Based LIMS Adoption Across Europe

Retrieved on: 
Friday, February 16, 2024

DUBLIN, Feb. 16, 2024 /PRNewswire/ -- The "Europe Laboratory Information Management System (LIMS) Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 16, 2024 /PRNewswire/ -- The "Europe Laboratory Information Management System (LIMS) Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • This report offers market size & forecast data for the Europe laboratory information management system (LIMS) market.
  • The laboratory information management system (LIMS) is a software-based laboratory and information management system which supports modern laboratory operations.
  • Who are the key players in the Europe laboratory information management system (LIMS) market?

BostonGene Announces Publication in Nature

Retrieved on: 
Friday, February 16, 2024

BostonGene , a leading provider of AI-based molecular and immune profiling solutions, today announced the online publication of the manuscript “ Clinical trial links oncolytic immunoactivation to survival in glioblastoma ,” in Nature, an international journal publishing peer-reviewed research in all fields of science and technology prioritizing originality, significance, interdisciplinary relevance, timeliness, accessibility, sophistication, and groundbreaking findings.

Key Points: 
  • BostonGene , a leading provider of AI-based molecular and immune profiling solutions, today announced the online publication of the manuscript “ Clinical trial links oncolytic immunoactivation to survival in glioblastoma ,” in Nature, an international journal publishing peer-reviewed research in all fields of science and technology prioritizing originality, significance, interdisciplinary relevance, timeliness, accessibility, sophistication, and groundbreaking findings.
  • Utilization of immunotherapy for GBM has been challenging due to the scarcity of infiltrating antitumor lymphocytes caused by a highly immunosuppressive or “lymphocyte-depleted” tumor microenvironment (TME).
  • "BostonGene's innovative RNA-seq analytics lent novel insights into the dynamic changes associated with CAN-3110 therapy within the glioblastoma microenvironment," said Nathan Fowler, MD, Chief Medical Officer at BostonGene.
  • “Looking to the future, we are excited at the possibilities of harnessing oncolytic viruses to transform immunosuppressive microenvironments across a range of solid cancer types.”

EQS-News: Sartorius releases Annual Report for 2023

Retrieved on: 
Friday, February 16, 2024

The life science group Sartorius has released its Annual Report for 2023 today.

Key Points: 
  • The life science group Sartorius has released its Annual Report for 2023 today.
  • Sartorius is a leading international partner of life sciences research and biopharmaceutical manufacturing.
  • Sartorius regularly expands its portfolio through the acquisition of complementary technologies.
  • In 2023, the company generated sales revenue of around 3.4 billion euros.

IonQ Opens Doors to First Dedicated Quantum Computing Manufacturing Facility in the U.S.

Retrieved on: 
Thursday, February 15, 2024

IonQ (NYSE: IONQ), a leader in the quantum computing industry, today announced the opening of the United States’ first quantum computing manufacturing facility, located in Bothell, Washington, a suburb of Seattle.

Key Points: 
  • IonQ (NYSE: IONQ), a leader in the quantum computing industry, today announced the opening of the United States’ first quantum computing manufacturing facility, located in Bothell, Washington, a suburb of Seattle.
  • View the full release here: https://www.businesswire.com/news/home/20240215594253/en/
    IonQ Opens Doors to First Dedicated Quantum Computing Manufacturing Facility in the U.S. (Photo: Business Wire)
    The facility will be IonQ’s second quantum data center providing cloud access to IonQ customers, and the primary production engineering location in the U.S.
  • “The Seattle facility represents a tangible realization of IonQ’s commitment to commercializing quantum and getting quantum computers into the hands of customers,” said IonQ CEO Peter Chapman.
  • To learn more about how you can get started on an IonQ system today, please contact us directly at: https://ionq.com/get-ready .

Labroots Announces Agenda for its 7th Annual Drug Discovery & Development Virtual Event on February 21, 2024

Retrieved on: 
Thursday, February 15, 2024

YORBA LINDA, Calif., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 7th annual event in the Drug Discovery & Development Virtual Event Series. Hosted on February 21st and free to attend, attendees will experience the forefront of pharmaceutical innovation joining industry and academic leaders from around the world debating the latest, insightful scientific breakthroughs in this ever-evolving field.

Key Points: 
  • Focusing from pre-clinical development to clinical development, advances in the field of drug discovery and development will be explored shaping current and future challenges in drug research
    YORBA LINDA, Calif., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Labroots , the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 7th annual event in the Drug Discovery & Development Virtual Event Series .
  • The 2024 informative agenda covers a range of sessions spanning areas including Emerging Modalities in Drug Discovery and Preclinical Development, New Methods in Pharmacogenomics, and Biomarker Applications.
  • Use the hashtag #LRdrug to follow the conversation and connect with other members of the global Drug Discovery & Development community!
  • Follow @DrugDiscoveryLR on Twitter and @DrugDiscoveryandDevelopment on Facebook to connect with our specialist Drug Discovery & Development writers and stay up to date with the latest Trending News in Drug Discovery & Development.

IDEXX Launches Vello™, an Innovative Pet Owner Engagement Software Solution, Streamlining How Practices and Clients Connect

Retrieved on: 
Thursday, February 15, 2024

WESTBROOK, Maine, Feb. 15, 2024 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announces the launch of Vello, a software solution that seamlessly connects veterinary practices and clients through modern, digital tools. As the only pet owner engagement solution purpose-built for IDEXX practice management software, Vello enables veterinary practices using ezyVet®, Neo®, and Cornerstone® software to communicate efficiently with pet owners in a single, easy-to-use system. With software-supported engagement across the life stages of a pet, pet owners become informed partners in care—supporting better health outcomes. IDEXX's Vello solution will be available as a new subscription service for ezyVet, Neo, and Cornerstone software in the U.S. in March 2024 and Canada in Q2.

Key Points: 
  • As the only pet owner engagement solution purpose-built for IDEXX practice management software, Vello enables veterinary practices using ezyVet®, Neo®, and Cornerstone® software to communicate efficiently with pet owners in a single, easy-to-use system.
  • With software-supported engagement across the life stages of a pet, pet owners become informed partners in care—supporting better health outcomes.
  • Now, Vello software allows practices to engage with pet owners pre- and post-visit through an intuitive solution purpose-built for their practice management software.
  • Online scheduling that enables pet owners to conveniently request appointments directly from health service reminders or through the Vello software.

City of Hope Research Featuring the Successful Treatment of the Oldest Patient to Achieve Remission for Leukemia and HIV Published in The New England Journal of Medicine (NEJM)

Retrieved on: 
Wednesday, February 14, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240214747351/en/
    "City of Hope Patient" Paul Edmonds with City of Hope doctors, Jana K. Dickter, M.D., and Monzr Al Malki, M.D.
  • Edmonds is also the person who had HIV the longest — for over 31 years — among these five patients.
  • Known as the “City of Hope patient” among these five patients, Edmonds received a transplant at City of Hope on Feb. 6, 2019, and is now considered to be cured of leukemia.
  • City of Hope has exceptional transplant outcomes year after year, according to the Center for International Blood & Marrow Transplant Research.

PIH Health, Medline expand prime vendor partnership to service all points of care

Retrieved on: 
Wednesday, February 14, 2024

NORTHFIELD, Ill., Feb. 14, 2024 /PRNewswire/ -- Medline today announced it has expanded its prime vendor agreement with California-based healthcare network PIH Health. As the exclusive medical and surgical supplies distribution partner across PIH Health's inpatient acute care hospitals for more than 10 years, the new agreement will expand Medline's distribution services and solutions to the system's full network of laboratories, outpatient physician offices and post-acute care facilities.

Key Points: 
  • NORTHFIELD, Ill., Feb. 14, 2024 /PRNewswire/ -- Medline today announced it has expanded its prime vendor agreement with California-based healthcare network PIH Health .
  • As the exclusive medical and surgical supplies distribution partner across PIH Health's inpatient acute care hospitals for more than 10 years, the new agreement will expand Medline's distribution services and solutions to the system's full network of laboratories, outpatient physician offices and post-acute care facilities.
  • Building on the longstanding partnership, the two organizations will collaborate to identify new strategies for consolidating distribution and efficiently integrating all points of care into the health system's overall supply chain operations.
  • "At Medline, we remain dedicated to delivering exceptional service and support for the ongoing transformation of PIH Health's supply chain, which is a testament to PIH Health leadership's vision and commitment to excellence."

VANTAGE® TO EXHIBIT AT BEAUTY ACCELERATE TRADESHOW

Retrieved on: 
Wednesday, February 14, 2024

DEERFIELD, Ill., Feb. 14, 2024 /PRNewswire/ -- Vantage, a leading global supplier of naturally derived specialty ingredients, formulation components and expertise will showcase its SPARK INNOVATION platform at the upcoming Beauty Accelerate tradeshow in Los Angeles on March 6-7, 2024. Designed to meet the needs of emerging and quick-growing brands looking for off-the shelf solutions, this fast formulation capability offers full-service product development solutions using the Company's wide range of natural ingredients.

Key Points: 
  • Vantage will showcase its SPARK INNOVATION® fast formulation platform at Beauty Accelerate at Booth 116 in Los Angeles, March 6-7, 2024.
  • DEERFIELD, Ill., Feb. 14, 2024 /PRNewswire/ -- Vantage, a leading global supplier of naturally derived specialty ingredients, formulation components and expertise will showcase its SPARK INNOVATION platform at the upcoming Beauty Accelerate tradeshow in Los Angeles on March 6-7, 2024.
  • Finally, Vantage representatives will present natural and customized solutions for bespoke botanical extracts, vegetable oil compositions and naturally derived milk-inspired formulations that are designed to help beauty brands to differentiate their products in the highly competitive beauty market.
  • Upon request, Vantage also offers individualized R&D and marketing support for each one, supported by scientists located in its twelve laboratories around the globe.

IperionX Drives Towards Commercial Scale Titanium Metal Production

Retrieved on: 
Wednesday, February 14, 2024

This large-scale titanium furnace is expected to be installed within the Titanium Production Facility during the second quarter, paving the way for the production of titanium metal in mid-2024.

Key Points: 
  • This large-scale titanium furnace is expected to be installed within the Titanium Production Facility during the second quarter, paving the way for the production of titanium metal in mid-2024.
  • A critical IperionX production asset, this large-scale, industrial titanium furnace leverages patented company technologies, such as HAMR1 and HSPT2, to produce sustainable, high-quality and high-strength titanium metal products at commercial scale.
  • In 2023, the IperionX technical team successfully completed two full-scale titanium production test runs that surpassed the core target production parameters for the Titanium Production Facility.
  • Construction Progress - Titanium Production Facility, Virginia
    Construction of the Titanium Production Facility is advancing to schedule, with the HAMR titanium furnace expected to be commissioned and to produce first titanium metal in mid-2024.